Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Cited by (324)

Items 101–200 of 324

1. The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer
   Smadar Geva, Anna Belilovski Rozenblum, Tal Twito, Roxana Grinberg, Addie Dvir, Lior Soussan‐Gutman, Maya Ilouze, Laila C. Roisman, Elizabeth Dudnik, Alona Zer et al. · 2018 · Journal of Thoracic Oncology
2. Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling
   Stephan B. Dreyer, Nigel Balfour Jamieson, Lisa Evers, Fraser R. Duthie, Susie Cooke, John Marshall, Dario Beraldi, Stephen Richard Knight, Rosanna Upstill‐Goddard, Euan J. Dickson et al. · 2019 · Chinese Clinical Oncology
3. RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer
   Kazuhiko Nakagawa, Ernest Nadal, Edward B. Garon, Makoto Nishio, Takashi Seto, Nobuyuki Yamamoto, Keunchil Park, Jin‐Yuan Shih, Luis G Paz-Ares, Bente Frimodt‐Moller et al. · 2021 · Clinical Cancer Research
4. Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
   Bin-Chi Liao, Sebastian Griesing, James Chih‐Hsin Yang · 2019 · Therapeutic Advances in Medical Oncology
5. Circulating tumor DNA as liquid biopsy in lung cancer: Biological characteristics and clinical integration
   Changshu Li, Jun Shao, Peiyi Li, Jiaming Feng, Jingwei Li, Chengdi Wang · 2023 · Cancer Letters
6. Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA
   Muyun Peng, Yuancai Xie, Xiaohua Li, Youhui Qian, Xiaonian Tu, Xumei Yao, Fangsheng Cheng, Feiyue Xu, Deju Kong, Bing He et al. · 2019 · Journal of Medical Genetics
7. The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas
   Baharia Mograbi, Simon Heeke, Paul M Hofman · 2021 · Diagnostics
8. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
   Joan M. Irizarry-Alvarado, Jamie P. Dwyer, Lisa M. Brumble, Salvador Álvarez, Julio Mendez · 2009 · PubMed
9. Circulating tumor DNA testing in advanced non-small cell lung cancer
   Everett James Moding, Maximilian Diehn, Heather A. Wakelee · 2018 · Lung Cancer
10. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer
    Xiaofen Zhang, Shaoqing Ju, Xudong Wang, Hui Cong · 2019 · Clinical and Experimental Medicine
11. Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
    Paul M Hofman · 2021 · Cells
12. Extracellular Vesicles: New Players in Lymphomas
    Victor Navarro‐Tableros, Yonathan Gomez, Giovanni Camussi, Maria Felice Brizzi · 2018 · International Journal of Molecular Sciences
13. Diagnostic and Economic Value of Biomarker Testing for Targetable Mutations in Non-Small-Cell Lung Cancer: a Literature Review
    Ying Zheng, Helene Vioix, Frank X. Liu, Barinder Singh, Sakshi Sharma, D P Sharda · 2021 · Future Oncology
14. Liquid biopsies in lung cancer—time to implement research technologies in routine care?
    Linda Köhn, Mikael Johansson, Kjell Grankvist, Jonas A. Nilsson · 2017 · Annals of Translational Medicine
15. Next Generation Sequencing: From Research Area to Clinical Practice.
    Chiara Di Resta, Maurizio Ferrari · 2018 · Europe PMC (PubMed Central)
16. Radiomics for prediction of response to EGFR-TKI based on metastasis/brain parenchyma (M/BP)-interface
    Ying Fan, Zilong Zhao, Xingling Wang, Hua Ai, Chunna Yang, Yahong Luo, Xiran Jiang · 2022 · La radiologia medica
17. PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer
    Stephan B. Dreyer, Nigel Balfour Jamieson, Susanna L. Cooke, Juan W. Valle, C. J. McKay, Andrew Victor Biankin, David Kuang-Fu Chang · 2019 · Clinical Oncology
18. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages
    Meng Yang, Ümit Topaloĝlu, William Jeffrey Petty, Matthew Pagni, Kristie L. Foley, Stefan C. Grant, Mac Robinson, Rhonda Lynn Bitting, Alexandra Thomas, Angela Tatiana Alistar et al. · 2017 · Journal of Hematology & Oncology
19. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA
    Wey Cheng Sim, Chet Hong Loh, Grace Li-Xian Toh, Chia Wei Lim, Akhil Chopra, Alex Yuan Chi Chang, Liuh Ling Goh · 2018 · Lung Cancer
20. Monitoring Melanoma Using Circulating Free DNA
    Russell J. Diefenbach, Jenny Lee, Helen Rizos · 2018 · American Journal of Clinical Dermatology
21. Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)
    Finn Mildner, Sieghart Sopper, Arno Amann, Andreas Pircher, Georg Pall, Stefan Koeck, Erin Naismith, Dominik Georg Friedrich Wolf, Gabriele Gamerith · 2020 · Critical Reviews in Oncology/Hematology
22. Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer
    Lin Chen, Xun Shi, Jun Zhao, Qiong He, Yun Fan, Weizhen Xu, Yang Washington Shao, Xinmin Yu, Ying Jin · 2020 · Frontiers in Oncology
23. Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment
    Zhenghang Wang, Xiaochen Zhao, Chan Gao, Jifang Gong, Xicheng Wang, Jing Gao, Zhongwu Li, Jie Wang, Bo Yeun Yang, Lei Wang et al. · 2020 · Journal for ImmunoTherapy of Cancer
24. The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment
    M. Abbasian, A. Ardekani, Navid Sobhani, R. Roudi · 2022 · Cancers
25. Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors
    Cathy Zhou, Zilong Yuan, Weijie Ma, Lihong Qi, Angelique Mahavongtrakul, Ying Li, Hong Li, Jay Gong, Reggie R. Fan, Jin Li et al. · 2018 · Journal of Hematology & Oncology
26. Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement
    Neal Navani, Rachel Butler, Salma Ibrahimo, Anjali Verma, Matthew Evans, Gary Joseph Doherty, Samreen I. Ahmed · 2022 · Lung Cancer
27. Survival impact of postoperative radiotherapy timing in pediatric and adolescent medulloblastoma
    Alexander Li-Che Chin, Everett James Moding, Sarah S. Donaldson, Iris C. Gibbs, Scott G. Soltys, Susan M. Hiniker, Erqi Liu Pollom · 2018 · Neuro-Oncology
28. Circulating DNA in EGFR-mutated lung cancer
    Aditi Puri Singh, Shenduo Li, Haiying Cheng · 2017 · Annals of Translational Medicine
29. Feasibility of monitoring advanced melanoma patients using cell‐free DNA from plasma
    Tara C. Gangadhar, Samantha L. Savitch, Stephanie S. Yee, Wei Xu, Alexander Chan Chi Huang, Shannon Harmon, David B. Lieberman, Devon Soucier, Ryan Fan, Taylor A. Black et al. · 2017 · Pigment Cell & Melanoma Research
30. Next-generation sequencing for the general cancer patient.
    Monica Avila, Funda Meric‐Bernstam · 2019 · PubMed
31. Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients
    Paul M Hofman · 2021 · Cancers
32. Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors
    Bardia Yousefi, Michael Joseph Lariviere, Eric A. Cohen, Thomas H. Buckingham, Stephanie S. Yee, Taylor A. Black, Austin L. Chien, Peter Benjamin Noël, Wei‐Ting Hwang, Sharyn I. Katz et al. · 2021 · Scientific Reports
33. Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma
    Stephen Joseph Bagley, Jacob Edward Till, Aseel Abdalla, Hareena K Sangha, Stephanie S. Yee, Jake M. Freedman, Taylor A. Black, Jasmin Hussain, Zev A. Binder, Steven S. Brem et al. · 2021 · Neuro-Oncology Advances
34. Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
    Yize Li, Shengnan Kong, Yunpeng Liu, Yue Yang, Hongmei Zhang · 2023 · Journal of Clinical Medicine
35. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay
    Helei Hou, Xiaonan Yang, Jinping Zhang, Zhe Zhang, Xiaomei Xu, Xiaoping Zhang, Chuantao Zhang, Dong Liu, Wei‐Hua Yan, Hongmei Zhu et al. · 2017 · Scientific Reports
36. Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers
    Jill Kolesar, Keng Hee Peh, Levin Thomas, Gayathri Baburaj, Nayonika Mukherjee, Raveena Kantamneni, Shirley Christabel Lewis, Ananth Pai, Karthik Udupa, Naveena A. N. Kumar et al. · 2022 · Molecular Cancer
37. Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test
    Damien Vasseur, Hela Sassi, Arnaud Bayle, Marco Tagliamento, Benjamin Besse, Christophe Marzac, Ahmadreza Arbab, Nathalie Auger, Sophie Cotteret, Mihaela D. Aldea et al. · 2022 · Cells
38. The role of circulating free DNA in the management of NSCLC
    Riziero Esposito Abate, Raffaella Pasquale, Francesca Fenizia, Anna Maria Rachiglio, Cristin Roma, Francesca Bergantino, Laura Forgione, Matilde Lambiase, Alessandra Sacco, Maria Carmela Piccirillo et al. · 2018 · Expert Review of Anticancer Therapy
39. Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma
    Yu Chun Xiong, Chengrong Xie, Sheng Zhang, Chen Jin, Zhenyu Yin · 2019 · Cancer Management and Research
40. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib
    Huafei Chen, Wenxian Wang, C. Xu, Lichao Huang, Xiaofeng Li, Gang Lan, Zhanqiang Zhai, You‐cai Zhu, Kaiqi Du, Lei Lei et al. · 2020 · Lung Cancer
41. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer
    Jhanelle E. Gray, Jeffrey C. Thompson, Erica L. Carpenter, Ehab Elkhouly, Charu Aggarwal · 2021 · The Oncologist
42. ctDNA Detection in Microfluidic Platform: A Promising Biomarker for Personalized Cancer Chemotherapy
    Samla Gauri, Mohd Ridzuan Ahmad · 2020 · Journal of Sensors
43. Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
    Alvida Qvick, Bianca Stenmark, Jessica Carlsson, Johan Isaksson, Christina Karlsson, Gisela Helenius · 2021 · Molecular Medicine
44. Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer
    Zeyun Lin, Yuqin Li, Shiqi Tang, Qiuhua Deng, Juhong Jiang, Chengzhi Zhou · 2023 · Lung Cancer
45. Clinical utility of circulating cell-free DNA in advanced colorectal cancer
    Allan Andresson Lima Pereira, Maria Pia Morelli, Michael James Overman, Bryan K. Kee, David R. Fogelman, Eduardo Vilar, Imad Shureiqi, Kanwal P. S. Raghav, Cathy Eng, Shanequa Manuel et al. · 2017 · PLoS ONE
46. Peptide-Affinity Precipitation of Extracellular Vesicles and Cell-Free DNA Improves Sequencing Performance for the Detection of Pathogenic Mutations in Lung Cancer Patient Plasma
    Cathy Taylor, Simi M. Chacko, Michelle Davey, Jacynthe Lacroix, Alexander MacPherson, Nicholas Finn, Gabriel Wajnberg, Anirban Ghosh, Nicolas Crapoulet, Stephen M. Lewis et al. · 2020 · International Journal of Molecular Sciences
47. MET alterations in advanced non-small cell lung cancer
    M Sakamoto, Tejas Patil · 2023 · Lung Cancer
48. A microfluidic-based filtration system to enrich for bone marrow disseminated tumor cells from breast cancer patients
    Sreeraj G. Pillai, Chidananda M. Siddappa, Cynthia X. Ma, Jackie Snider, Madhurima Kaushal, Mark A. Watson, Rebecca Aft · 2021 · PLoS ONE
49. Complementing Tissue Testing With Plasma Mutation Profiling Improves Therapeutic Decision-Making for Patients With Lung Cancer
    Yukti Choudhury, Min‐Han Tan, Jun Shi, Augustine Kim Huat Tee, Kao Chin Ngeow, Jonathan Poh, Ruth Rosalyn Goh, Jamie Chen Yee Mong · 2022 · Frontiers in Medicine
50. Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC
    Ying Fan, Xinti Wang, Yue Dong, E-Nuo Cui, Huan Wang, Xinyan Sun, Juan Su, Yahong Luo, Tao Yu, Xiran Jiang · 2023 · European Radiology
51. Circulating Tumor DNA in Non–Small-Cell Lung Cancer: A Primer for the Clinician
    Aditi Puri Singh, Haiying Cheng, Xiaoling Guo, Benjamin Philip Levy, Balázs Halmos · 2017 · JCO Precision Oncology
52. Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?
    Wafik S. El‐Deiry, Barry S. Taylor, Joel W. Neal · 2017 · American Society of Clinical Oncology Educational Book
53. EGFR inhibition in NSCLC: New findings…. and opened questions?
    Francesco Passiglia, Angela Listì, Marta Castiglia, Alessandro Perez, Sérgio Rizzo, Viviana Bazan, Antonio Dello Russo · 2017 · Critical Reviews in Oncology/Hematology
54. Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA
    Michael David Offin, Jacob J. Chabon, Pedram Razavi, James M. Isbell, Charles M. Rudin, Maximilian Diehn, Bob T. Li · 2017 · Journal of Oncology
55. Epidermal Growth Factor Receptor Mutations
    Erin M. McLoughlin, Ryan D. Gentzler · 2020 · Thoracic surgery clinics/Thorac. surg. clin.
56. Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications
    Matthias Scheffler, Marcel Wiesweg, Sebastian Yves Friedrich Michels, Lucia Nogová, Anna Kron, Thomas Herold, Andreas Hans Scheel, Martin Metzenmacher, Wilfried Eberhardt, Henning Reis et al. · 2022 · Lung Cancer
57. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations
    Joseph J. Park, Alec Chu, Jinju Li, Alicia Ali, Rana R. McKay, Clara Hwang, Matthew Labriola, Albert Jang, Deepak Kilari, George Mo et al. · 2024 · JCO Precision Oncology
58. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
    Can Pi, Mingfeng Zhang, Xiaoxiao Peng, Yichen Zhang, Chong‐Rui Xu, Qing Hua Zhou · 2017 · Expert Review of Molecular Diagnostics
59. Kinetics of Plasma cfDNA Predicts Clinical Response in Non-Small Cell Lung Cancer Patients
    Xiaorong Zhou, Chenchen Li, Zhao Zhang, Daniel Yuhang Li, Jinwei Du, Ping Ding, Haiyan Meng, Hui Xu, Ronglei Li, Effie Ho et al. · 2020 · Scientific Reports
60. Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation
    Ângela Carvalho, Gabriela Ferreira, Duarte Seixas, Catarina Guimarães‐Teixeira, Rui Henrique, Fernando Jorge Monteiro, Cármen Jerónimo · 2021 · Cancers
61. Meeting an un-MET need: Targeting MET in non-small cell lung cancer
    Elena Michaels, Christine M. Bestvina · 2022 · Frontiers in Oncology
62. The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer
    Mengyuan Lyu, Jian Hua Zhou, Ning Kang, Binwu Ying · 2019 · OncoTargets and Therapy
63. Cell-Free Circulating Tumour DNA Blood Testing to Detect EGFR T790M Mutation in People With Advanced Non-Small Cell Lung Cancer: A Health Technology Assessment.
    2020 · PubMed Central
64. Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer
    Ying Fan, Rui Sun, Zhizhong Wang, Yuying Zhang, Xiao Xiao, Yizhe Liu, Beibei Xin, Hui Xiong, Daru Lu, Jie Ma · 2022 · Journal of Cancer Research and Clinical Oncology
65. Brain‐Tumor Interface‐Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR‐TKI and T790M Resistance Mutation in Non‐Small Cell Lung Carcinoma Brain Metastasis
    Ying Fan, Xinti Wang, Chunna Yang, Huanhuan Chen, Huan Wang, Xiaoyu Wang, Shaoping Hou, Lihua Wang, Yahong Luo, Xianzheng Sha et al. · 2023 · Journal of Magnetic Resonance Imaging
66. Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profiling
    Alexandre Pellan Cheng, Adam J. Widman, Anushri Arora, Itai Rusinek, Aaron Sossin, Srinivas Rajagopalan, Nicholas Midler, William F. Hooper, Rebecca L. Murray, Daniel Halmos et al. · 2025 · Nature Methods
67. Detection and application of circulating tumor cell and circulating tumor DNA in the non-small cell lung cancer.
    Yuting Zhang, Hongmei Zheng, Yuting Zhan, Mengping Long, Sile Liu, Junmi Lu, Hongjing Zang, Songqing Fan · 2018 · Europe PMC (PubMed Central)
68. Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung Cancer
    Gabriela Fernandes, Natália Alves Martins, Conceição Souto Moura, Susana Guimarães, Joana Pereira Reis, Ana Justino, Maria João Pina, Adriana Magalhães, Henrique Queiroga, José Carlos Machado et al. · 2021 · Cancers
69. New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)—Positive Cancer
    Matteo Villa, Geeta G. Sharma, Chiara Manfroni, Diego Luigi Cortinovis, Luca Mologni · 2021 · Cancers
70. Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non–Small-Cell Lung Cancer: A Multicenter Case Series
    Miriam T. Jacobs, Nisha Anjali Mohindra, Lindsey Shantzer, Ingrid L. Chen, Hardeep S. Phull, William Mitchell, Victoria M. Raymond, Kimberly C. Banks, Rebecca J. Nagy, Richard Burnham Lanman et al. · 2018 · JCO Precision Oncology
71. Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer
    Jennifer S. Winn, Zachary Hasse, Michael J. Slifker, Jianming Pei, Sebastian M. Arisi-Fernandez, Jacqueline N. Talarchek, Elias I. Obeid, Donald A. Baldwin, Yulan Gong, Eric A. Ross et al. · 2020 · International Journal of Molecular Sciences
72. Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs
    Zhenli Diao, Yanxi Han, Rui Zhang, Jinming Li · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
73. Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling
    Hai Thanh Tran, Vincent K. L. Lam, Yasir Y. Elamin, Lingzhi Hong, Rivka R. Colen, Nabil A. Elshafeey, Islam S. A. Hassan, Mehmet Altan, George R. Blumenschein, Waree Rinsurongkawong et al. · 2021 · JCO Precision Oncology
74. Detection and utility of cell-free and circulating tumour DNA in bone and soft-tissue sarcomas
    Tsoi, Kim M., Gokgoz, Nalan, Darville-O'Quinn, Paige, Prochazka, Patrick, Malekoltojari, Ainaz, Griffin, Anthony M., Ferguson, Peter C., Wunder, Jay S., Andrulis, Irene L. · 2021 · Bone & Joint Research
75. The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies
    Xuezheng Sun, Page E. Abrahamson, Nick Ballew, Linda Kalilani, Kelesitse Phiri, Kelly F. Bell, Alexander Slowley, Magdalena Zajac, Erin Wysong Hofstatter, Alexander Stojadinovic et al. · 2023 · Cancer Investigation
76. The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
    Zhen Wu, Yu Dai, Liang-An Chen · 2019 · Cancer Management and Research
77. Machine Learning-Assisted Dual-Marker Detection in Serum Small Extracellular Vesicles for the Diagnosis and Prognosis Prediction of Non-Small Cell Lung Cancer
    Wenzhe Li, Ling Zhu, Kaidi Li, Siyuan Ye, Huayi Wang, Yadong Wang, Jianchao Xue, Chen Wang, Shanqing Li, Naixin Liang et al. · 2022 · Nanomaterials
78. Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients
    Lei‐Yun Wang, Jiajia Cui, Ao-Xiang Guo, Ji‐Ye Yin · 2018 · OncoTargets and Therapy
79. Next-generation sequencing of circulating tumor DNA for detection of gene mutations in lung cancer: implications for precision treatment
    Jinhuo Lai, Bin Du, Yao Wang, Riping Wu, Zongyang Yu · 2018 · OncoTargets and Therapy
80. Non‑invasive detection of EGFR and TP53�mutations through the combination of plasma, urine and sputum in advanced non‑small cell lung cancer
    Zhen Wu, Zhen Yang, Chun‐Sun Li, Wei Ming Zhao, Zhi‑Xin Liang, Yu Dai, Jing Zeng, Qiang Zhu, Kai‐Ling Miao, Donghua Cui et al. · 2019 · Oncology Letters
81. The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
    Maria Gabriela O. Fernandes, Natália Alves Martins, José Carlos Machado, José Luís Costa, Venceslau Pinto Hespanhol · 2021 · Cancer Cell International
82. A liquid biopsy in primary lung cancer
    Kazue Yoneda, Naoko Imanishi, Yoshinobu Ichiki, Fumihiro Tanaka · 2018 · Surgery Today
83. Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry
    Justin J. Kim, Sara A. Walton, Navin R. Mahadevan, Jessica Haradon, Francesco Paoloni, Paul K. Paik, Jamie E. Chaft, Robert C. Hsu, Sarina Anne Piha-Paul, Pasi Antero Janne et al. · 2025 · Clinical Cancer Research
84. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results
    Edward B. Garon, Martin Reck, Kazuto Nishio, John Victor Heymach, Makoto Nishio, Silvia Novello, Luis G Paz-Ares, Sanjay Popat, Santiago Ponce-Aix, H. Graham et al. · 2023 · ESMO Open
85. Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer
    Melina Elpi Marmarelis, Jeffrey C. Thompson, Charu Aggarwal, Tracey L. Evans, Erica L. Carpenter, Roger B. Cohen, Corey Jay Langer, Joshua Michael Bauml · 2017 · Annals of Translational Medicine
86. Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology
    Dimosthenis E. Ziogas, Ioannis D Kyrochristos, Dimitrios H Roukos · 2018 · Drug Discovery Today
87. Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic
    Pooja Ghatalia, Chad H. Smith, Arthur Winer, Jiangtao Gou, Lesli Ann Kiedrowski, Michael J. Slifker, Patricia D. Saltzberg, Nicole Bubes, Fern M. Anari, Vineela Kasireddy et al. · 2019 · Frontiers in Oncology
88. Unique Genomic Alterations of Cerebrospinal Fluid Cell-Free DNA Are Critical for Targeted Therapy of Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
    Yongsheng Wang, Feng Jiang, Ruixue Xia, Ming Li, Chengyun Yao, Yan Li, Hui Li, Qi Zhao, Mingke Shi, Yanzhe Yu et al. · 2021 · Frontiers in Oncology
89. Sample types applied for molecular diagnosis of therapeutic management of advanced non-small cell lung cancer in the precision medicine
    Yanxi Han, Jinming Li · 2017 · Clinical Chemistry and Laboratory Medicine (CCLM)
90. RUMI is a novel negative prognostic marker and therapeutic target in non–small‐cell lung cancer
    May Chammaa, Agnes Malysa, Carlos Redondo, Hyejeong Jang, Wei Chen, Gerold Bepler, Rodrigo Fernandez‐Valdivia · 2018 · Journal of Cellular Physiology
91. Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells
    Ni Sima, Wei Sun, Kirill Gorshkov, Min Shen, Wei Huang, Wenge Zhu, Xing Xie, Wei Zheng, Xiaodong Cheng · 2018 · Translational Oncology
92. Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients
    Lanlan Liu, Xianzhi Xiong · 2021 · Current Oncology
93. Circulating tumor DNA: Where are we now? A mini review of the literature
    Gliceida Galarza Fortuna, Kathrin Dvir · 2020 · World Journal of Clinical Oncology
94. Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing
    Nina Pujol, Simon Heeke, Christophe Bontoux, Jacques Boutros, Marius Ilié, Véronique Hofman, Charles‐Hugo Marquette, Paul M Hofman, Jonathan Benzaquen · 2022 · Journal of Personalized Medicine
95. Liquid biopsy is a valuable tool in the diagnosis and management of lung cancer
    Matthew J. Cecchini, Eunhee S. Yi · 2020 · Journal of Thoracic Disease
96. Novel technologies in cfDNA analysis and potential utility in clinic
    Jie Li, Mengyue Xu, Junya Peng, Jingqiao Wang, Yupei Zhao, Wenming Wu, Xun Lan · 2021 · Chinese Journal of Cancer Research
97. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Nan Zhang, Jinwei Zhang, Guoqing Wang, Xin He, Yin Mi, Ying Cao, Xiaoxu Yu · 2022 · Frontiers in Oncology
98. Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
    Samantha I. Liang, Zoe Quandt, Sara Wienke, Jing Wang, Sean Gordon, Reagan M. Barnett, Jude Masannat, Kyle Chang, Carin R. Espenschied, Katie Quinn et al. · 2025 · Cancer Research Communications
99. Identification of genetic variations associated with drug resistance in non-small cell lung cancer patients undergoing systemic treatment
    Ruihan Luo, Chuang Ge, Xiao Xiao, Jing Song, Shiqi Miao, Yongyao Tang, Jiayi Lai, Weiqi Nian, Fangzhou Song, Longke Ran · 2021 · Briefings in Bioinformatics
100. Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy
     Sissel Gyrid Freim Wahl, Hong Yan Dai, Elisabeth Fritzke Emdal, Anine Larsen Ottestad, Vibeke Grotnes Dale, Elin H. Richardsen, Tarje Onsøien Halvorsen, Bjørn Henning Grønberg · 2021 · The Journal of Pathology Clinical Research